Clinical Trial Update: Dual Inhibition of EGFR Signalling Using the Combination of Cetuximab and Erlotinib [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of cetuximab and erlotinib for metastatic colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Cetuximab (cetuximab)
• ERLOTINIB (Erlotinib)

Snippet

Sponsor: Austin Health | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: UNKNOWN